Biofourmis
1. Category: Artificial Intelligence, Machine Learning, mHealth, Personal Health, Predictive Analytics, Therapeutics, Wearables
2. Domain: IT health care
3. Founders: Kuldeep Singh Rajput, Wendou Niu
4. Established: Nov 27, 2015
5. Number of Employees: 101 – 250
6. Operating Status: Active
7. Funding status : Not disclosed
8. Website: Biofourmis.com
9. Country: Greater Boston Area, East Coast, New England
10. Latest in News: Biofourmis Partners with ImagineMIC to Pioneer Collaborative Remote Patient Monitoring Model
Biofourmis a digital health company augmenting personalized patient care therapies with Digital Therapeutics for better management of patients with complex chronic conditions and helps to develop and delivers clinically validated software-based therapeutics to provide cost-effective solutions for payers.
They are esteemed towards continuous discovering, development and delivers clinically validated software-based therapeutics to enable better outcomes for patients. They have accelerated research and drug development for biopharmaceutical companies, advanced tools for clinicians to deliver personalized care, and, ultimately, better outcomes for patients.
The company raised US$45 Million in venture capital from leading Venture Capital firms including Sequoia Capital, MassMutual Ventures, Singapore Govt-linked EDBI, Aviva plc, and Mayo Clinic Ventures.
Biovitals is the backbone of the Biofourmis, which spans a number of therapeutic areas and disease states, including heart failure, acute coronary syndrome, COPD and chronic pain.
The companies’ solutions are advanced and highly sophisticated AI-powered health analytics ecosystem that predicts clinical exacerbation in advance of a critical event. Their robust digital therapeutics products and pipeline covers multiple therapeutic areas including heart failure, coronary artery disease, COPD and pain.
The HealthCare systems can prevent disease, manage complex chronic populations, and minimize unnecessary readmissions and ER visits and enables real-time monitoring and management of patients to measure effectiveness, dosage variances, and adverse reactions at the individual level.
For Payers it is clear that, which treatments are working for which patients, so you can take a more personalized approach to your near ones. However, AI-powered tools and insight have potential to improve clinical outcomes for your patients.
Biofourmis’ launched artificial intelligence-powered RhythmAnalytics® to provide clinical decision support those IDs cardiac arrhythmias and other issues requiring intervention in 2020
This new model uses advanced deep learning architecture to detect dozens of cardiac arrhythmias and also provide clinical decision support for the board-certified emergency physicians, physician assistants, nurse practitioners and specialty-trained registered nurses in the MIC.
The technology can be integrated as a cloud-based API into existing cardiac monitoring solutions and significantly improving the accuracy and scalability of ECG analysis and reducing rates of misinterpretation and inappropriate patient management.
